Global X Data Center & Digital Infra ETF vs Vaxcyte Inc. Common Stock — how do they compare? Global X Data Center & Digital Infra ETF trades at $26.12 (market cap $2.11B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 5× Global X Data Center & Digital Infra ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Global X Data Center & Digital Infra ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 17 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| DTCR | PCVX | |
|---|---|---|
Market Cap | $2.11B | $10.51B |
Volume | 655,653 | 2,644,694 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $73.82 |
52-Week Low | $19.73 | $40.32 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
DTCR trades at $27.33, down 1.44% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Recent news highlights DTCR's position as a key ETF for AI infrastructure exposure, with coverage emphasizing its blend of real estate stability and growth from digital infrastructure sectors. The ETF has gained attention as a picks-and-shovels play in the AI boom.
The outlook for DTCR appears favorable given sustained AI infrastructure investment, though risks include sector volatility and interest rate sensitivity. Analyst sentiment remains positive with buy recommendations citing long-term growth potential from diversified technology and real estate holdings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →